Highlights

[PHARMA] YoY Quarter Result on 2010-09-30 [#3]


View:


Show?  YoY % Horiz. %

Quarter Result
30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 30/09/08 30/09/07 CAGR
Revenue 440,807 426,460 371,432 334,337 329,962 314,288 334,700 4.69%
  YoY % 3.36% 14.82% 11.10% 1.33% 4.99% -6.10% -
  Horiz. % 131.70% 127.42% 110.97% 99.89% 98.58% 93.90% 100.00%
PBT 13,461 28,493 15,646 15,405 9,427 17,641 31,915 -13.39%
  YoY % -52.76% 82.11% 1.56% 63.41% -46.56% -44.73% -
  Horiz. % 42.18% 89.28% 49.02% 48.27% 29.54% 55.27% 100.00%
Tax -9,291 -2,957 -4,687 -6,970 -3,032 -6,593 -10,354 -1.79%
  YoY % -214.20% 36.91% 32.75% -129.88% 54.01% 36.32% -
  Horiz. % 89.73% 28.56% 45.27% 67.32% 29.28% 63.68% 100.00%
NP 4,170 25,536 10,959 8,435 6,395 11,048 21,561 -23.93%
  YoY % -83.67% 133.01% 29.92% 31.90% -42.12% -48.76% -
  Horiz. % 19.34% 118.44% 50.83% 39.12% 29.66% 51.24% 100.00%
NP to SH 3,751 25,247 10,811 8,586 6,059 10,590 21,302 -25.11%
  YoY % -85.14% 133.53% 25.91% 41.71% -42.79% -50.29% -
  Horiz. % 17.61% 118.52% 50.75% 40.31% 28.44% 49.71% 100.00%
Tax Rate 69.02 % 10.38 % 29.96 % 45.25 % 32.16 % 37.37 % 32.44 % 13.40%
  YoY % 564.93% -65.35% -33.79% 40.70% -13.94% 15.20% -
  Horiz. % 212.76% 32.00% 92.36% 139.49% 99.14% 115.20% 100.00%
Total Cost 436,637 400,924 360,473 325,902 323,567 303,240 313,139 5.69%
  YoY % 8.91% 11.22% 10.61% 0.72% 6.70% -3.16% -
  Horiz. % 139.44% 128.03% 115.12% 104.08% 103.33% 96.84% 100.00%
Net Worth 473,402 496,469 464,092 424,488 407,858 374,393 335,784 5.89%
  YoY % -4.65% 6.98% 9.33% 4.08% 8.94% 11.50% -
  Horiz. % 140.98% 147.85% 138.21% 126.42% 121.46% 111.50% 100.00%
Dividend
30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 30/09/08 30/09/07 CAGR
Div 7,760 11,764 - - 28,903 - - -
  YoY % -34.03% 0.00% 0.00% 0.00% 0.00% 0.00% -
  Horiz. % 26.85% 40.70% 0.00% 0.00% 100.00% - -
Div Payout % 206.90 % 46.60 % - % - % 477.03 % - % - % -
  YoY % 343.99% 0.00% 0.00% 0.00% 0.00% 0.00% -
  Horiz. % 43.37% 9.77% 0.00% 0.00% 100.00% - -
Equity
30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 30/09/08 30/09/07 CAGR
Net Worth 473,402 496,469 464,092 424,488 407,858 374,393 335,784 5.89%
  YoY % -4.65% 6.98% 9.33% 4.08% 8.94% 11.50% -
  Horiz. % 140.98% 147.85% 138.21% 126.42% 121.46% 111.50% 100.00%
NOSH 258,689 117,646 106,933 106,924 107,049 106,969 106,937 15.85%
  YoY % 119.89% 10.02% 0.01% -0.12% 0.07% 0.03% -
  Horiz. % 241.91% 110.01% 100.00% 99.99% 100.10% 100.03% 100.00%
Ratio Analysis
30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 30/09/08 30/09/07 CAGR
NP Margin 0.95 % 5.99 % 2.95 % 2.52 % 1.94 % 3.52 % 6.44 % -27.29%
  YoY % -84.14% 103.05% 17.06% 29.90% -44.89% -45.34% -
  Horiz. % 14.75% 93.01% 45.81% 39.13% 30.12% 54.66% 100.00%
ROE 0.79 % 5.09 % 2.33 % 2.02 % 1.49 % 2.83 % 6.34 % -29.30%
  YoY % -84.48% 118.45% 15.35% 35.57% -47.35% -55.36% -
  Horiz. % 12.46% 80.28% 36.75% 31.86% 23.50% 44.64% 100.00%
Per Share
30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 30/09/08 30/09/07 CAGR
RPS 170.40 362.49 347.35 312.69 308.23 293.81 312.99 -9.63%
  YoY % -52.99% 4.36% 11.08% 1.45% 4.91% -6.13% -
  Horiz. % 54.44% 115.82% 110.98% 99.90% 98.48% 93.87% 100.00%
EPS 1.45 21.46 10.11 8.03 5.66 9.90 19.92 -35.36%
  YoY % -93.24% 112.27% 25.90% 41.87% -42.83% -50.30% -
  Horiz. % 7.28% 107.73% 50.75% 40.31% 28.41% 49.70% 100.00%
DPS 3.00 10.00 0.00 0.00 27.00 0.00 0.00 -
  YoY % -70.00% 0.00% 0.00% 0.00% 0.00% 0.00% -
  Horiz. % 11.11% 37.04% 0.00% 0.00% 100.00% - -
NAPS 1.8300 4.2200 4.3400 3.9700 3.8100 3.5000 3.1400 -8.60%
  YoY % -56.64% -2.76% 9.32% 4.20% 8.86% 11.46% -
  Horiz. % 58.28% 134.39% 138.22% 126.43% 121.34% 111.46% 100.00%
Adjusted Per Share Value based on latest NOSH - 261,230
30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 30/09/08 30/09/07 CAGR
RPS 168.74 163.25 142.19 127.99 126.31 120.31 128.12 4.69%
  YoY % 3.36% 14.81% 11.09% 1.33% 4.99% -6.10% -
  Horiz. % 131.70% 127.42% 110.98% 99.90% 98.59% 93.90% 100.00%
EPS 1.44 9.66 4.14 3.29 2.32 4.05 8.15 -25.07%
  YoY % -85.09% 133.33% 25.84% 41.81% -42.72% -50.31% -
  Horiz. % 17.67% 118.53% 50.80% 40.37% 28.47% 49.69% 100.00%
DPS 2.97 4.50 0.00 0.00 11.06 0.00 0.00 -
  YoY % -34.00% 0.00% 0.00% 0.00% 0.00% 0.00% -
  Horiz. % 26.85% 40.69% 0.00% 0.00% 100.00% - -
NAPS 1.8122 1.9005 1.7766 1.6250 1.5613 1.4332 1.2854 5.89%
  YoY % -4.65% 6.97% 9.33% 4.08% 8.94% 11.50% -
  Horiz. % 140.98% 147.85% 138.21% 126.42% 121.46% 111.50% 100.00%
Price Multiplier on Financial Quarter End Date
30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 30/09/08 30/09/07 CAGR
Date 30/09/13 28/09/12 30/09/11 30/09/10 30/09/09 30/09/08 28/09/07 -
Price 4.8200 7.5500 5.9000 4.9800 4.0900 3.2400 3.2700 -
P/RPS 2.83 2.08 1.70 1.59 1.33 1.10 1.04 18.14%
  YoY % 36.06% 22.35% 6.92% 19.55% 20.91% 5.77% -
  Horiz. % 272.12% 200.00% 163.46% 152.88% 127.88% 105.77% 100.00%
P/EPS 332.41 35.18 58.36 62.02 72.26 32.73 16.42 65.01%
  YoY % 844.88% -39.72% -5.90% -14.17% 120.78% 99.33% -
  Horiz. % 2,024.42% 214.25% 355.42% 377.71% 440.07% 199.33% 100.00%
EY 0.30 2.84 1.71 1.61 1.38 3.06 6.09 -39.43%
  YoY % -89.44% 66.08% 6.21% 16.67% -54.90% -49.75% -
  Horiz. % 4.93% 46.63% 28.08% 26.44% 22.66% 50.25% 100.00%
DY 0.62 1.32 0.00 0.00 6.60 0.00 0.00 -
  YoY % -53.03% 0.00% 0.00% 0.00% 0.00% 0.00% -
  Horiz. % 9.39% 20.00% 0.00% 0.00% 100.00% - -
P/NAPS 2.63 1.79 1.36 1.25 1.07 0.93 1.04 16.71%
  YoY % 46.93% 31.62% 8.80% 16.82% 15.05% -10.58% -
  Horiz. % 252.88% 172.12% 130.77% 120.19% 102.88% 89.42% 100.00%
Price Multiplier on Announcement Date
30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 30/09/08 30/09/07 CAGR
Date 19/11/13 06/11/12 01/11/11 04/11/10 13/11/09 24/11/08 22/11/07 -
Price 4.7200 8.2500 5.9000 4.9200 3.9300 3.3500 3.4200 -
P/RPS 2.77 2.28 1.70 1.57 1.28 1.14 1.09 16.80%
  YoY % 21.49% 34.12% 8.28% 22.66% 12.28% 4.59% -
  Horiz. % 254.13% 209.17% 155.96% 144.04% 117.43% 104.59% 100.00%
P/EPS 325.52 38.44 58.36 61.27 69.43 33.84 17.17 63.22%
  YoY % 746.83% -34.13% -4.75% -11.75% 105.17% 97.09% -
  Horiz. % 1,895.86% 223.88% 339.90% 356.84% 404.37% 197.09% 100.00%
EY 0.31 2.60 1.71 1.63 1.44 2.96 5.82 -38.63%
  YoY % -88.08% 52.05% 4.91% 13.19% -51.35% -49.14% -
  Horiz. % 5.33% 44.67% 29.38% 28.01% 24.74% 50.86% 100.00%
DY 0.64 1.21 0.00 0.00 6.87 0.00 0.00 -
  YoY % -47.11% 0.00% 0.00% 0.00% 0.00% 0.00% -
  Horiz. % 9.32% 17.61% 0.00% 0.00% 100.00% - -
P/NAPS 2.58 1.95 1.36 1.24 1.03 0.96 1.09 15.43%
  YoY % 32.31% 43.38% 9.68% 20.39% 7.29% -11.93% -
  Horiz. % 236.70% 178.90% 124.77% 113.76% 94.50% 88.07% 100.00%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.


NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ Δ & YoY Δ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.



  Be the first to like this.
 


APPS
I3 Messenger
Individual or Group chat with anyone on I3investor
MQ Trader
View Trading Signals and run Live Backtest
MQ Affiliate
Earn rewards with MQ Affiliate Program
 
 

293  614  561  681 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 AT 0.095+0.005 
 JAKS-OR 0.260.00 
 LCTITAN 2.13-0.27 
 SUPERMX-C1I 0.145-0.01 
 LUSTER 0.165-0.005 
 MAHSING 0.96-0.04 
 HWGB 0.78+0.065 
 DGSB 0.225+0.01 
 DATAPRP 0.195-0.025 
 KSTAR 0.43+0.06 

FEATURED POSTS

1. The Equity Market Index Benchmark in Malaysia CMS
2. Trading Scenarios of Derivatives Bursa Derivatives Education Series
3. Derivatives 101 Bursa Derivatives Education Series
4. Why Trade FKLI? Bursa Derivatives Education Series
5. MQ Trader - Introduction to MQ Trader Affiliate Program MQ Trader Announcement!

TOP ARTICLES

1. Supermax: my revised target price - Koon Yew Yin Koon Yew Yin's Blog
2. A LOOK AT CALVIN TAN RESEARCH STOCK PICKS (AS RECORDED BY PHILIP NOT PERFECTLY BUT CLEAR ENOUGH THE INVESTMENT APPROACH OF CALVIN TAN
3. Supermax: The Best Is Yet To Come- Myth or Truth Van Gogh of Financial
4. US has 2 Incurable Chronic Diseases - Koon Yew Yin Koon Yew Yin's Blog
5. [Humbled Investor] Supermx - Superb results - Estimation on Next QR Results HumbledInvestor
6. DOW CRASHED BY 650 POINTS ? NO FEAR AT ALL IF YOU KNOW THIS STOCK PROSPERED DURING ASIAN FINANCIAL CRISIS & SUBPRIME CRISIS OF 2007/8 COLLAPSE (WHAT? THE INVESTMENT APPROACH OF CALVIN TAN
7. LUXCHEM RESULT VERSUS HARTALEGA RESULT (COMPARE & CONTRAST) Calvin Tan Research THE INVESTMENT APPROACH OF CALVIN TAN
8. Traders Brief 27 Oct 2020 - Volatility Ahead Amid Internal and External Headwinds HLBank Research Highlights
PARTNERS & BROKERS